Cargando…

Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab

Giant cell carcinoma, a rare variant of nonsmall cell lung carcinoma (NSCLC), is characterized by aggressive progression and poor response to conventional chemotherapy. This report is the first to describe a patient with NSCLC and giant cell features who was successfully treated with pembrolizumab,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakayama, Shingo, Sasaki, Mamoru, Morinaga, Shojiroh, Minematsu, Naoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875061/ https://www.ncbi.nlm.nih.gov/pubmed/29736285 http://dx.doi.org/10.1155/2018/5863015

Ejemplares similares

Tracheal granular cell tumour presenting with throat discomfort
por: Nakagawara, Kensuke, et al.
Publicado: (2019)

Asymptomatic Pulmonary Artery Intimal Sarcoma with Chest Wall Metastasis as an Initial Manifestation: An Autopsy Case
por: Kakimoto, Tomoo, et al.
Publicado: (2018)

Pattern of FDG-PET uptake in lipoid pneumonia simulating lung cancer
por: Nakagawara, Kensuke, et al.
Publicado: (2020)

A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review
por: Kakimoto, Tomoo, et al.
Publicado: (2019)

Pulmonary sclerosing pneumocytoma demonstrating intratumoral hematoma
por: Lee, Ko, et al.
Publicado: (2019)

Long-term Findings in Bullous Sarcoidosis: A Case Report and Literature Review
por: Higuchi, Hiroyuki, et al.
Publicado: (2022)

Successful treatment of metastatic bladder pleomorphic giant cell carcinoma with pembrolizumab
por: Nezu, Kunihisa, et al.
Publicado: (2021)

Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic
por: Ksienski, Doran, et al.
Publicado: (2022)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens
por: Xu, Huihong, et al.
Publicado: (2018)

Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy
por: Zhao, Jing, et al.
Publicado: (2017)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Zhang, Jie, et al.
Publicado: (2021)

Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report
por: McBride, Ali, et al.
Publicado: (2021)

Clinicopathological features and outcomes in advanced nonsmall cell lung cancer with tailored therapy
por: Bala, Stalin, et al.
Publicado: (2016)

A Case of Nonsmall-Cell Lung Cancer with Anaphylaxis after 41 Courses of Pembrolizumab along with Adrenal Insufficiency as an Immune-Related Adverse Event
por: Nakamura, Tomoaki, et al.
Publicado: (2022)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2022)

Pulmonary Mycobacterium avium infection demonstrating unusual lobar caseous pneumonia
por: Okuzumi, Shinichi, et al.
Publicado: (2016)

Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images
por: Sha, Lingdao, et al.
Publicado: (2019)

The Effect of Pembrolizumab in Absence of Programmed Death 1 Receptor
por: Al Attar, Layth, et al.
Publicado: (2018)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

Modern therapies of nonsmall cell lung cancer
por: Jachowski, Andrzej, et al.
Publicado: (2023)

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
por: Sul, Joohee, et al.
Publicado: (2016)

Lower neutrophil‐to‐lymphocyte ratio and positive programmed cell death ligand‐1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma
por: Miyama, Yu, et al.
Publicado: (2022)

Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
por: Sugisaka, Jun, et al.
Publicado: (2019)

Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma
por: Cui, Yong-Xin, et al.
Publicado: (2020)

Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
por: Yoshida, Kazushige, et al.
Publicado: (2019)

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
por: Incorvaia, Lorena, et al.
Publicado: (2019)

microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1
por: Jiang, Kexin, et al.
Publicado: (2021)

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab
por: Hatayama, Tomoya, et al.
Publicado: (2020)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer
por: Gong, Hua C., et al.
Publicado: (2011)

The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer
por: Escobar, Mauricio, et al.
Publicado: (2011)

Gemcitabine for the treatment of advanced nonsmall cell lung cancer
por: Toschi, Luca, et al.
Publicado: (2009)

Thyroid Metastasis from Nonsmall Cell Lung Cancer
por: Namad, Tariq, et al.
Publicado: (2013)

An IMRT/VMAT Technique for Nonsmall Cell Lung Cancer
por: Zhao, Nan, et al.
Publicado: (2015)

Bronchoscopic treatment of inoperable nonsmall cell lung cancer
por: Kniese, Christopher M., et al.
Publicado: (2020)

Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
por: Ferrucci, Pier Francesco
Publicado: (2023)

Commentary on “Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma”
por: Peña-Cardelles, Juan Francisco, et al.
Publicado: (2022)

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
por: Burtness, Barbara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h14cfdjhqs7q8ffog06uhd6u2e